MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. [electronic resource]
Producer: 20110915Description: 2799-806 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Pancreatic Ductal -- drug therapy
- Cell Cycle Proteins -- antagonists & inhibitors
- Cell Line, Tumor
- Deoxycytidine -- administration & dosage
- Disease Progression
- Drug Synergism
- Female
- Genes, p53
- Humans
- Mice
- Mice, Nude
- Mutation -- physiology
- Neoplasms -- drug therapy
- Nuclear Proteins -- antagonists & inhibitors
- Pancreatic Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrazoles -- administration & dosage
- Pyrimidines -- administration & dosage
- Pyrimidinones
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.